Wei Liu
Vascular Neurology · Louisville, KYNPI 1720277684
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (49.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 23.8%. Reporting peaked in 2022 at $2,872 and has fallen 95.4% since, to $132 in 2025.
Across 74 payments — averaging $99.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Shionogi Inc$1K
- Biogen$1K
- Janssen Research & Development, LLC$968
- ZOLL Medical Corporation$747
- BD$374
- plus $1K from 10 others
Across 60 payments — averaging $5197.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$129K
- Biogen$114K
- E.r. Squibb & Sons, L.L.C.$52K
- Sunovion Pharmaceuticals Inc.$16K
What the payments were for
- Consulting fees$1,24517%
- Travel & lodging$3,62049%
- Food & beverage$2,52534%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 20 | $1,762 |
| Shionogi Inc | 3 | $1,461 |
| Biogen | 10 | $1,014 |
| Janssen Research & Development, LLC | 8 | $968 |
| ZOLL Medical Corporation | 1 | $747 |
| BD | 1 | $374 |
| UCB, Inc. | 15 | $356 |
| Abbott | 2 | $148 |
| Terumo Medical Corporation | 1 | $134 |
| Chiesi USA, Inc. | 1 | $126 |
| Genentech USA, Inc. | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 5 | $68 |
| AstraZeneca(2 entities) | 3 | $47 |
| Stryker | 1 | $24 |
| Balt USA, LLC | 1 | $21 |
| Johnson & Johnson | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Pipeline$449
- GLIDESHEATH SLENDER$134
- CLEVIPREX 25MG/50ML$126
- CLEVIPREX 50MG/100ML$126
- Confirm Rx$125
How this compares
Too few vascular neurology providers in Kentuckyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 41 | $44,275 |
| XareltoRivaroxaban | 32 | $26,072 |
| BrilintaTicagrelor | 12 | $9,472 |
| Butalb-Acetaminoph-Caff-CodeinButalbit/Acetamin/Caff/Codeine | 23 | $957 |
| Memantine Hcl | 39 | $856 |
| ClopidogrelClopidogrel Bisulfate | 125 | $795 |
| Atorvastatin Calcium | 73 | $694 |
| Rosuvastatin Calcium | 48 | $586 |
| Gabapentin | 55 | $451 |
| Pantoprazole Sodium | 73 | $446 |
| Amlodipine Besylate | 57 | $239 |
| Lisinopril | 42 | $106 |
| Topiramate | 16 | $91 |
| Baclofen | 16 | $77 |
| Carvedilol | 11 | $70 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $16 | $26,07232 claims |
| AstraZenecaBrilinta | $47 | $9,47212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few vascular neurology providers in Kentuckyon file to place this against a meaningful peer group, so we don't.
Other vascular neurology in Louisville
- Tamika BurrusLouisville$267
- Roberto Chulluncuy RivasLouisville$55
- Larry GoldsteinLexington$29K
- Mais Al-KawazLexington$4K
- Suhas GangadharaLexington$3K
- Homa SadeghianLexington$2K
- Tanya WarwickAshland$1K
- Jessica LeeLexington$918
- Richard MurphyLexington$108
- Kevin O'ConnorLexington$14
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.